Aleglitazar
- Generic Name
- Aleglitazar
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23NO5S
- CAS Number
- 475479-34-6
- Unique Ingredient Identifier
- 41T4OAG59U
- Background
Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes. In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects and toxicity.
- Indication
Investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity.
A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)
- Conditions
- Diabetes Mellitus Type 2, Kidney Disease, Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01893242
A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT01871428
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 7
- Registration Number
- NCT01871415
A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 57
- Registration Number
- NCT01729403
A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities
- Conditions
- Cardiovascular Disease, Diabetes Mellitus Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-10-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1999
- Registration Number
- NCT01715818
A Pharmacokinetic Study of Aleglitazar in Healthy Chinese Volunteers
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01711775
A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT01701739
A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 196
- Registration Number
- NCT01691755
A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy
- First Posted Date
- 2012-09-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 197
- Registration Number
- NCT01691989
A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease
- First Posted Date
- 2012-09-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01680978
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.